Related Experiment Video
Updated: Aug 26, 2026
Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System
Published on: July 30, 2018
Delivery of DNA to tumor cells in vivo using adeno-associated virus
Selvarangan Ponnazhagan1, Frank Hoover
1Department of Pathology, University of Alabama, Birmingham, AL, USA.
Abstract:
The number of published studies on transduction of tumor cells in vivo using recombinant adeno-associated virus (rAAV) vectors is very limited compared with those that have been published on targeting normal cells. A major reason for this can be attributed to the biology of the vector itself. AAV, being a nonpathogenic vector capable of providing transgene integration and long-term expression, is ideally suited for the correction of metabolic defects either to replace a defective protein/enzyme or to elevate their otherwise suboptimal levels in the system. However, increased understanding of both the biology of tumor progression and potential utility of AAV-based vectors suggests that this vector can also be wisely used for cancer gene therapy.
Insights
Recombinant adeno-associated virus (rAAV) vectors show promise for cancer gene therapy. Despite limited research on tumor cell transduction, rAAV
Area of Science:
- Oncology
- Gene Therapy
- Virology
Background:
- Limited studies explore recombinant adeno-associated virus (rAAV) vector transduction in tumor cells compared to normal cells.
- Adeno-associated virus (AAV) is a nonpathogenic vector suitable for gene therapy due to transgene integration and long-term expression.
Purpose of the Study:
- To highlight the potential of rAAV vectors in cancer gene therapy.
- To address the limited research on rAAV transduction of tumor cells in vivo.
Main Methods:
- Review of existing literature on AAV vector biology and tumor progression.
- Exploration of AAV vector characteristics relevant to cancer gene therapy applications.
Main Results:
- AAV vectors are well-suited for correcting metabolic defects.
- Growing understanding of tumor biology suggests AAV vectors can be utilized for cancer gene therapy.
Conclusions:
- rAAV vectors hold significant, yet largely unexplored, potential for cancer gene therapy.
- Further research is warranted to leverage AAV vector capabilities for oncological treatments.
